 Home > Active Ingredient News > Infection > J INTERN MED: Treatment and prognosis of HIV-associated pulmonary hypertension

J INTERN MED: Treatment and prognosis of HIV-associated pulmonary hypertension

 Last Update: 2022-04-18
 Source: Internet
 Author: User

Tags

treatment

center veterinary medicine

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Pulmonary hypertension (pulmonary hypertension) is an independent predictor of death in HIV- infected
patients .

HIV is the leading cause of pulmonary hypertension (HIV-pulmonary hypertension) worldwide

Infect

In a research article published recently in the Journal of Internal Medicine, the authoritative journal in the field of internal medicine, researchers aimed to describe the characteristics, treatment patterns and prognosis of a group of HIV-pulmonary hypertension patients and compare them with a group of equivalent idiopathic patients.
Patients with sexual/familial pulmonary hypertension were compared
.

We retrospectively analyzed and compared demographic .
HIV-pulmonary hypertension overall survival (OS) was up to 5 years and was compared to an age- and sex-matched population with idiopathic pulmonary hypertension/familial pulmonary hypertension .
The researchers also analyzed changes in treatment patterns in HIV-pulmonary hypertension patients after 2010 and their impact on OS .

statistics

Compared with idiopathic/familial pulmonary hypertension (n=739), HIV-pulmonary hypertension patients (n=132) were younger, predominantly male, and had better functional status
.

Clinical presentation, hemodynamics, and respiratory function were similar between groups

Thus, HIV-pulmonary hypertension patients are mainly young men
.

Despite better functional status, short-term outcomes were similar to age- and sex-matched patients with idiopathic/familial pulmonary hypertension

HIV-pulmonary hypertension patients are predominantly young men

Original source:

Salvador María Lázaro.

Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 years of evidence from the REHAP registry

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

DL-Menthol89-78-1

CAS No.: 89-78-1

$20-21/MT FOB

Phenol CAS NO. 108-95-2 Factory Supply 99% High Quality liquid

CAS No.: 108-95-2

Industrial Grade

$1-1.2/KG FOB

Entecavir//Hunan Warrant Chiral Pharma

CAS No.: 209216-23-9

Pharmacy Grade

$65-80/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

single use technology(195)

united states logo(227)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.